BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22192091)

  • 1. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan.
    Muro Y; Sugiura K; Hoshino K; Akiyama M; Tamakoshi K
    Arthritis Res Ther; 2011; 13(6):R214. PubMed ID: 22192091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease.
    Sato S; Hoshino K; Satoh T; Fujita T; Kawakami Y; Fujita T; Kuwana M
    Arthritis Rheum; 2009 Jul; 60(7):2193-200. PubMed ID: 19565506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody.
    Cao H; Pan M; Kang Y; Xia Q; Li X; Zhao X; Shi R; Lou J; Zhou M; Kuwana M; Ding X; Zheng J
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1602-10. PubMed ID: 22623119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
    Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
    Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?
    Ikeda S; Arita M; Morita M; Ikeo S; Ito A; Tokioka F; Noyama M; Misaki K; Notohara K; Ishida T
    BMC Pulm Med; 2015 Dec; 15():159. PubMed ID: 26651481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody.
    Nakashima R; Imura Y; Kobayashi S; Yukawa N; Yoshifuji H; Nojima T; Kawabata D; Ohmura K; Usui T; Fujii T; Okawa K; Mimori T
    Rheumatology (Oxford); 2010 Mar; 49(3):433-40. PubMed ID: 20015976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis.
    Ceribelli A; Fredi M; Taraborelli M; Cavazzana I; Tincani A; Selmi C; Chan JY; Chan EK; Satoh M; Franceschini F
    Clin Exp Rheumatol; 2014; 32(6):891-7. PubMed ID: 25151986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis.
    Labrador-Horrillo M; Martinez MA; Selva-O'Callaghan A; Trallero-Araguas E; Balada E; Vilardell-Tarres M; Juárez C
    J Immunol Res; 2014; 2014():290797. PubMed ID: 24741583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.
    Gil B; Merav L; Pnina L; Chagai G
    Clin Rheumatol; 2016 Aug; 35(8):2125-2130. PubMed ID: 25846833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.
    Hoshino K; Muro Y; Sugiura K; Tomita Y; Nakashima R; Mimori T
    Rheumatology (Oxford); 2010 Sep; 49(9):1726-33. PubMed ID: 20501546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
    Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
    Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis.
    Takada T; Aoki A; Asakawa K; Sakagami T; Moriyama H; Narita I; Sato S
    Respir Med; 2015 Sep; 109(9):1174-80. PubMed ID: 26187000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis.
    Teruya A; Kawamura K; Ichikado K; Sato S; Yasuda Y; Yoshioka M
    Chest; 2013 Dec; 144(6):1934-1936. PubMed ID: 24297126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.
    Koga T; Fujikawa K; Horai Y; Okada A; Kawashiri SY; Iwamoto N; Suzuki T; Nakashima Y; Tamai M; Arima K; Yamasaki S; Nakamura H; Origuchi T; Hamaguchi Y; Fujimoto M; Ishimatsu Y; Mukae H; Kuwana M; Kohno S; Eguchi K; Aoyagi K; Kawakami A
    Rheumatology (Oxford); 2012 Jul; 51(7):1278-84. PubMed ID: 22378718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.
    Xu Y; Yang CS; Li YJ; Liu XD; Wang JN; Zhao Q; Xiao WG; Yang PT
    Clin Rheumatol; 2016 Jan; 35(1):113-6. PubMed ID: 26660480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of therapeutic plasma exchange in clinically amyopathic dermatomyositis with MDA-5 antibody: A case report and review of the literature.
    Fine A; Karp JK; Peedin AR
    J Clin Apher; 2020 Sep; 35(5):483-487. PubMed ID: 33617011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody.
    Hosono Y; Nakashima R; Serada S; Murakami K; Imura Y; Yoshifuji H; Ohmura K; Naka T; Mimori T
    J Autoimmun; 2017 Feb; 77():116-122. PubMed ID: 27919567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission.
    Muro Y; Sugiura K; Hoshino K; Akiyama M
    Rheumatology (Oxford); 2012 May; 51(5):800-4. PubMed ID: 22210662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis.
    Horai Y; Koga T; Fujikawa K; Takatani A; Nishino A; Nakashima Y; Suzuki T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Ida H; Kakugawa T; Sakamoto N; Ishimatsu Y; Mukae H; Hamaguchi Y; Fujimoto M; Kuwana M; Origuchi T; Kohno S; Kawakami A
    Mod Rheumatol; 2015 Jan; 25(1):85-9. PubMed ID: 24716595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.